Satsuma Pharmaceuticals, Inc. – NASDAQ:STSA

Add to watchlist

Market closed

Open in about 9 hours

+0.94%

month

+6.00%

quarter

-66.88%

year

Market Cap	36.46M
Enterprise value	8.29M

P/E	-0.37
EV/Sales	N/A
EV/EBITDA	-0.08
Price/Sales	N/A
Price/Book	0.52
PEG ratio	0.01
EPS	-1.96

Revenue	N/A
EBITDA	-52.73M
Income	-63.33M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA): Profit margin
Jun 2022	0	-16.13M
Sep 2022	0	-14.87M
Dec 2022	0	-22.50M
Mar 2023	0	-9.82M

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA): Debt to assets
Jun 2022	80151000	7.96M	9.93%
Sep 2022	75037000	6.65M	8.87%
Dec 2022	54939000	8.11M	14.77%
Mar 2023	43479000	5.83M	13.41%

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA): Cash Flow
Jun 2022	-11.68M	14.56M	-478K
Sep 2022	-13.41M	20.51M	9.7M
Dec 2022	-12.09M	-12.05M	17K
Mar 2023	-11.38M	14.48M	0

Satsuma Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Satsuma Pharmaceuticals
Employees

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA): Employee count
Aug 2023	25
Sep 2023	25
Oct 2023	25
Nov 2023	25
Dec 2023	25
Jan 2024	25
Feb 2024	25
Mar 2024	25
Apr 2024	25
May 2024	25
Jun 2024	25
Jul 2024	25

Satsuma Pharmaceuticals
Hedge Funds Holdings Q1 2023

23.21% -39.06%

of STSA is owned by hedge funds

18 -16

hedge funds hold STSA stock

7.43M -12.40M

shares is hold by hedge funds

STSA hedge funds holdings changes

Satsuma Pharmaceuticals
Insider Trading

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA): Insider trades (number of shares)
Period	Buy	Sel
Nov 2022	6590000	3250000
Jun 2023	52530894	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	8 Jun 2023	SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 10 percent owner 10 percent owner	Common Stock	8,423,732	$0.91	$7,665,596
Purchase	6 Jun 2023	TAKANASHI KEN director, 10 percent owner: director, 10 percent owner:	Common Stock, $0.0001 par value	22,053,581	$0.91	$20,068,759
Purchase	6 Jun 2023	SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 10 percent owner 10 percent owner	Common Stock	22,053,581	$0.91	$20,068,759
Purchase	21 Nov 2022	LEONARD BRADEN MICHAEL director director	Common Stock	150,000	$0.71	$106,800
Purchase	15 Nov 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	300,694	$0.63	$188,836
Purchase	15 Nov 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	531,000	$0.63	$336,654
Purchase	14 Nov 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	5,608,306	$0.69	$3,869,731
Sale	14 Nov 2022	COMMODORE CAPITAL LP 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	3,250,000	$0.71	$2,294,500
Purchase	24 Nov 2021	COMMODORE CAPITAL LP 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	2,922	$5.42	$15,837
Purchase	22 Nov 2021	COMMODORE CAPITAL LP 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	9,979	$5.49	$54,785

STSA insider trading transactions

Satsuma Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application Compositions, Devices, and Methods for Treating or Preventing Headaches Filling date: 20 Jul 2020 Issue date: 5 Nov 2020	20 Jul 2020	5 Nov 2020
Application	Application INTRANASAL DHE FOR THE TREATMENT OF HEADACHE Filling date: 14 Feb 2020 Issue date: 11 Jun 2020	14 Feb 2020	11 Jun 2020
Application	Application Compositions, Devices, and Methods for Treating or Preventing Headaches Filling date: 11 Dec 2019 Issue date: 11 Jun 2020	11 Dec 2019	11 Jun 2020
Application	Application Intranasal DHE for the Treatment of Headache Filling date: 16 May 2019 Issue date: 12 Sep 2019	16 May 2019	12 Sep 2019

STSA patents

Satsuma Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q4 2013 31 Jan 2014	Q4 2013 Earnings Call Transcript
Q3 2013 25 Oct 2013	Q3 2013 Earnings Call Transcript
Q2 2013 26 Jul 2013	Q2 2013 Earnings Call Transcript
Q1 2013 26 Apr 2013	Q1 2013 Earnings Call Transcript

STSA earnings call transcripts

Satsuma Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. John A. Kollins (1963) Pres, Chief Executive Officer & Director	62	$585,790
Dr. Detlef F. Albrecht (1961) Chief Medical Officer	64	$501,150
Mr. Thomas P. O'Neil (1965) Chief Financial Officer	60	$436,960

Satsuma Pharmaceuticals
Latest News

Tuesday, 26 November 2024
09:00	Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura	prnewswire.com
Wednesday, 30 October 2024
20:00	Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura	prnewswire.com
Tuesday, 8 October 2024
08:50	Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs	prnewswire.com
Thursday, 13 June 2024
08:00	Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting	prnewswire.com
Friday, 25 November 2022
09:43	Best Penny Stocks To Buy Now? 7 Insider Picks In November	PennyStocks
Monday, 21 November 2022
10:06	Penny Stocks To Buy: 7 Insider Picks For November 2022	PennyStocks
Monday, 14 November 2022
11:40	Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?	InvestorPlace
Tuesday, 6 September 2022
08:02	Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference	GlobeNewsWire
Wednesday, 11 May 2022
16:05	Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference	GlobeNewsWire
Tuesday, 8 February 2022
08:30	Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference	GlobeNewsWire
Tuesday, 12 October 2021
16:15	Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors	GlobeNewsWire
Tuesday, 28 September 2021
16:05	Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference	GlobeNewsWire
Wednesday, 8 September 2021
16:05	Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

When is Satsuma Pharmaceuticals's next earnings date?

Unfortunately, Satsuma Pharmaceuticals's (STSA) next earnings date is currently unknown.
Does Satsuma Pharmaceuticals pay dividends?

No, Satsuma Pharmaceuticals does not pay dividends.
How much money does Satsuma Pharmaceuticals make?

Satsuma Pharmaceuticals has a market capitalization of 36.46M.
What is Satsuma Pharmaceuticals's stock symbol?

Satsuma Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "STSA".
What is Satsuma Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Satsuma Pharmaceuticals?

Shares of Satsuma Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Satsuma Pharmaceuticals's key executives?
Satsuma Pharmaceuticals's management team includes the following people:
- Mr. John A. Kollins Pres, Chief Executive Officer & Director(age: 62, pay: $585,790)
- Dr. Detlef F. Albrecht Chief Medical Officer(age: 64, pay: $501,150)
- Mr. Thomas P. O'Neil Chief Financial Officer(age: 60, pay: $436,960)
How many employees does Satsuma Pharmaceuticals have?

As Jul 2024, Satsuma Pharmaceuticals employs 25 workers.
When Satsuma Pharmaceuticals went public?

Satsuma Pharmaceuticals, Inc. is publicly traded company for more then 6 years since IPO on 13 Sep 2019.
What is Satsuma Pharmaceuticals's official website?

The official website for Satsuma Pharmaceuticals is satsumarx.com.
Where are Satsuma Pharmaceuticals's headquarters?

Satsuma Pharmaceuticals is headquartered at 400 Oyster Point Boulevard, South San Francisco, CA.
How can i contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals's mailing address is 400 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 04103200.

Satsuma Pharmaceuticals, Inc.

satsumarx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

+65 04103200

400 Oyster Point Boulevard
South San Francisco, CA 94080

CIK: 0001692830
ISIN: US80405P1075
CUSIP: 80405P107